James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Microsoft Corporation (MSFT) Stock Just Got a Whole Lot Stronger

MSFT stock will continue to ebb and flow, but its newest cloud product underscores why Microsoft is the king of business technology.

Why Tesla Inc (TSLA), Radius Health Inc (RDUS) and Blue Apron Holdings Inc (APRN) Are 3 of Today’s Worst Stocks

Blue Apron (APRN), Radius Health (RDUS) and Tesla (TSLA) shareholders all ended up wishing they had made it a three-day weekend.

Facebook Inc (FB) Stock Will Only Benefit As Snapchat Is Kept At Bay

Facebook (FB) is about to move directly into Snap's target market. That should assure FB stock holders that Snapchat poses no real threat.

Tesla Inc (TSLA) Stock Isn’t a Mere “Trade” Any Longer, for Better or Worse

Tesla (TSLA) is still a company with a compelling, long-term future despite TSLA stock tanking of late as certain realities set in.

Why Cyberark Software Ltd (CYBR), Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and Wynn Resorts, Limited (WYNN) Are 3 of Today’s Worst Stocks

Teva Pharmaceutical (TEVA), Wynn Resorts (WYNN) and Cyberark Software (CYBR) shareholders couldn't wait for the trading week to end.